Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CLN-617 |
| Synonyms | |
| Therapy Description |
CLN-617 is fusion protein comprising IL-2 and IL-12, as well as HSA and LAIR2, which potentially induces antitumor immune response (Cancer Res (2023) 83 (7_Supplement): 1839). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CLN-617 | CLN 617|CLN617 | CLN-617 is fusion protein comprising IL-2 and IL-12, as well as HSA and LAIR2, which potentially induces antitumor immune response (Cancer Res (2023) 83 (7_Supplement): 1839). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|